Please login to the form below

Not currently logged in
Email:
Password:

US recall of four children's products

Blacksmiths Brands has announced the recall of four children's products in the PediaCare line in the US

Blacksmiths Brands has announced the recall of four children's products in the PediaCare line in the US.

The voluntary recall comes after consultation with the US Food and Drug Administration (FDA) in what Blacksmiths Brands described as a 'precautionary step'.

The products had all been manufactured at the McNeil Consumer Healthcare Fort Washington, Pennsylvania, which has been temporarily shut down following an FDA inspection that found serious violations of the agency's good manufacturing practice requirements. McNeil Consumer Healthcare is a subsidiary of Johnson & Johnson.

The products involved in the recall are PediaCare Multi-Symptom Cold 4oz, PediaCare Long Acting Cough 4oz, PediaCare Decongestant 4oz and PediaCare Allergy and Cold 4oz.

In a statement, the company said: "the recall was not initiated as a result of any consumer reports of adverse events and no consumer complaints have been received about the safety or purity of the products."

Blacksmiths Brands have however advised customers who own any of the recalled products to dispose of them.

Peter Man, chairman and CEO of the company, said: "We're taking this voluntary step because protecting consumers and maintaining their trust are essential to our company's core values."

New arrangements for the manufacture of the recalled products have been made, with shipments expected to resume in July.

1st June 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics